AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06057675
Drug: Control (1% lidocaine with 1:100,000 epinephrine)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine)
Trial: NCT05977998
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IP (Intraperitoneal injection)
Trial: NCT05977998
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT05977998
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT05977998
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT06389877
Drug: BEAM-302
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEAM-302 is a lipid nanoparticle (LNP)-based therapy for the treatment of patients with AATD
Trial: NCT06292923
Drug: Foralumab
RxNorm normalized name: Foralumab
DrugBank: Foralumab (DB16170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foralumab nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).~Each Unidose device contains foralumab nasal solution, supplied at either 25 μg foralumab or 50 μg foralumab, sufficient for administration into a single nare.
Trial: NCT05972655
Drug: PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 antibody (Tislelizumab): 200mg d1 q3w
Trial: NCT05972655
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin: 130mg/m2 d1 q3w
Trial: NCT06408688
Drug: Immune Checkpoint Inhibitors
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cancer treatment.
Trial: NCT05587478
Drug: EDP-323
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT06541535
Drug: Fluid resuscitation with isotonic saline only
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers
Trial: NCT06143306
Drug: bupivacaine.
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: an ultrasound guided pectoserratus block with 25 mL of 0.25% bupivacaine
Trial: NCT06143306
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: an ultrasound guided pectoserratus block with 25 mL of saline
Trial: NCT05546866
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
Trial: NCT05126433
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lurbinectedin 3.2 mg/m\^2 intravenous (IV) every 3 weeks (Q3W)
Trial: NCT06494891
Drug: Intravenous Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive intravenous alcohol (6% ethanol v/v in saline; obtained from the Ronald Reagan UCLA Medical Center Investigational Drug Service) over the course of an alcohol challenge. During the challenge, participants will be administered alcohol designed to reach target BrACs of 20, 40, and 60 mg%, each over 15 min. After reaching the last target BrAC (0.06 g/dl) participants will complete a self-administration (SA) paradigm. Participants will be invited to work (button press) for alcohol according to a log-linear progressive ratio schedule.
Trial: NCT06251609
Drug: Naloxone 2 MG
RxNorm normalized name: naloxone 2 MG
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention consists of naloxone 2mg (2ml of 1mg/ml solution) administered by EMS personnel via the IV or IO route. The study intervention will be administered immediately (within 5 minutes) following the first dose of epinephrine. When naloxone hydrochloride is administered intravenously, the onset of action is generally apparent within two minutes. The naloxone will be administered following the first dose of epinephrine. The control is saline 2ml will be supplied in pre-filled syringes within numbered trial treatment packs. They will be identical in appearance to the naloxone syringes.
Trial: NCT06251609
Drug: Saline 2ml
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05253105
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
Trial: NCT05889455
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 100mg
Trial: NCT05533632
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.
Trial: NCT05621915
Drug: Nadroparin
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of nadroparin according to the ICU guidelines for thromboprophylaxis in ICU patients.
Trial: NCT04775381
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a cholecalciferol supplementation added to a fruit juice.
Trial: NCT06484673
Drug: Bosentan Dispersible Tablets
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet of 32 mg Bosentan
Trial: NCT06484673
Drug: Tracleer Tablet for Oral Suspension
RxNorm normalized name: bosentan Tablet for Oral Suspension [Tracleer]
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet of 32 mg Bosentan
Trial: NCT06527976
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomedine added to bupivacaine for adductor canal block
Trial: NCT06527976
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone added to bupivacaine for adductor canal block
Trial: NCT05321810
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
Trial: NCT05321810
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
Trial: NCT05326087
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
Trial: NCT05326087
Drug: MPA
RxNorm normalized name: MPA
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral MPA 10mg qd from Day 3 of ovarian stimulation till the day of ovulation trigger.
Trial: NCT06134271
Drug: Rezvilutamide
RxNorm normalized name: Rezvilutamide
DrugBank: Rezvilutamide (DB19133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezvilutamide 240mg qd
Trial: NCT06134271
Drug: Rezvilutamide plus abiraterone
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezvilutamide 240mg qd plus abiraterone 1000mg + prednisone 5 mg qd
Trial: NCT06241781
Drug: Gemcitabine injection
RxNorm normalized name: gemcitabine Injection
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine injection to treat cervical cancer
Trial: NCT05086952
Drug: Vericiguat (BAY1021189) - Intervention A
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fed state.
Trial: NCT05086952
Drug: Vericiguat (BAY1021189) - Intervention B
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 10 mg vericiguat high-concentration pediatric formulation (oral liquid formulation) in fasted state.
Trial: NCT05086952
Drug: Vericiguat (BAY1021189) - Intervention C
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 2.5 mg vericiguat low-concentration pediatric formulation (oral liquid formulation) in fed state.
Trial: NCT05086952
Drug: Vericiguat (Verquvo, BAY1021189) - Intervention D
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 10 mg vericiguat immediate release (IR) intact tablet in fed state.
Trial: NCT06441955
Drug: Ritonavir-Boosted Nirmatrelvir (Paxlovid)
RxNorm normalized name: nirmatrelvir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participant Selection and Baseline Data Collection: 6 months~* Longitudinal Observation and Intervention Implementation: 24 months~* Data Analysis and Findings Dissemination: 6 months Evaluate methodological advantages and limitations of an international pharmacosurveillance system based on electronic health records (EHRs). Adverse outcome; Electronic health record; Health informatics; Medication adherence; Pharmacoepidemiology; Pharmacosurveillance; Risk assessment.
Trial: NCT05256745
Drug: TCHP
RxNorm normalized name: Trastuzumab, Carboplatin, Docetaxel, and Pertuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)for 6 cycles, administered per USPI (Unites States Prescribing Information) Label
Trial: NCT02442752
Drug: Dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole capsules
Trial: NCT05606692
Drug: Propofol 1%
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
Trial: NCT05606692
Drug: Sevoflurane/Ultane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
Trial: NCT05606718
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: dapagliflozin 10mg once daily for 3 months after randomization
Trial: NCT05748665
Drug: Remimazolam besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Using remimazolam for induction of general anesthesia
Trial: NCT05748665
Drug: etomidate
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using etomidate for induction of general anesthesia
Trial: NCT05760378
Drug: Famitinib
RxNorm normalized name: Famitinib
DrugBank: Famitinib (DB11741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKI
Trial: NCT05760378
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD1 inhibitor
Trial: NCT05554419
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV or SC
Trial: NCT05554419
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05554419
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
RxNorm normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05554419
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06489197
Drug: Ivonescimab combined with albumin paclitaxel and cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivonescimab (20mg/kg, intravenous infusion, d1, Q3W) combined with albumin paclitaxel (220mg/m2, intravenous infusion, d1, Q3W) and cisplatin (75mg/m2, intravenous infusion, d1, Q3W), of which the maximum treatment time of chemotherapy was up to six cycles, and the maximum treatment time of AK112 was 24 months.
Trial: NCT05760144
Drug: DMPA
RxNorm normalized name: DMPA
DrugBank: Zytron (DB11768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will receive the contraceptive injectable, Depo-Provera at the enrollment visit and at 3, 6, 9, and 12 months. Participants will have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
Trial: NCT05760144
Drug: Etonogestrel implant
RxNorm normalized name: Etonogestrel Implant
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participant will receive the contraceptive implant, Nexplanon at the enrollment visits and have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
Trial: NCT06485635
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nintedanib
Trial: NCT06485635
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone
Trial: NCT04817644
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral semaglutide once daily for a total of 10 days
Trial: NCT06705062
Drug: reduced-dose PTCy
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receiving reduced dose of PTCy at 35mg.kg on day +3 and +4 together with tacrolimus starting from day+5 and single dose of anti-thymoglobin (ATG) 2.5mg/kg at 72 hours after documentation of neutrophil engraftment.
Trial: NCT06246357
Drug: [68Ga]Ga-PentixaFor
RxNorm normalized name: [68Ga]Ga-PentixaFor
DrugBank: Boclatixafortide gallium Ga-68 (DB19176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[68Ga\]Ga-PentixaFor will be injected intravenously approximately 60 minutes prior to scanning at a dose of 150 +/- 50 MBq (4 mCi +/- 1.4).
Trial: NCT05277922
Drug: Sodium Nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ascending doses of 4, 8 and 16 µg
Trial: NCT05728944
Drug: Aceclidine+Brimonidine combination ophthalmic solution
RxNorm normalized name: brimonidine Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Aceclidine + Brimonidine combination ophthalmic solution
Trial: NCT05728944
Drug: Aceclidine
RxNorm normalized name: Aceclidine
DrugBank: Aceclidine (DB13262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclidine ophthalmic solution
Trial: NCT05627557
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab will be administered as per schedule specified in the respective arm.
Trial: NCT05627557
Drug: MMF
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF will be administered as per schedule specified in the respective arm.
Trial: NCT05627557
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.
Trial: NCT05627557
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 80 mg (or 1.5 mg/kg if \</=45 kg) IV will be administered as premedication prior to infusions.
Trial: NCT06287606
Drug: Conventional OST
RxNorm normalized name: OST 577
DrugBank: Tuvirumab (DB17752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized into group Conventional OST will take a bowel preparation from the evening until the following morning.
Trial: NCT05627557
Drug: Diphenhydramine Hydrochloride
RxNorm normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions.
Trial: NCT06115031
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: General anesthesia will be induced and maintained using continuous infusion of intravenous remimazolam.
Trial: NCT06115031
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General anesthesia will be induced and maintained using target-controlled infusion of intravenous propofol.
Trial: NCT06145607
Drug: ABBV-CLS-7262
RxNorm normalized name: ABBV-CLS-7262
DrugBank: ABBV-CLS-7262 (DB18407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-CLS-7262
Trial: NCT05035485
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A rescue phenylephrine (75μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
Trial: NCT05019521
Drug: Danicopan
RxNorm normalized name: Danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT05335018
Drug: Glofitamab, Poseltinib, Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week.
Trial: NCT06517264
Drug: Antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic treatment, analgesics and hygienic-dietetic measures
Trial: NCT06254950
Drug: TAK-279
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-279 capsules.
Trial: NCT05529069
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05529069
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT06074497
Drug: KGX101 and Envafolimab
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B combination therapy KGX101 with Envafolibmab. 400mg to be injected subcutaneously with each target dose of KGX101 every 3 weeks. The dose escalation committee (DEC) may decide to increase the dosage to 600mg. based on PK, PD and safety data.
Trial: NCT06515990
Drug: DM005
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.
Trial: NCT05482893
Drug: Spevatamig (PT886)
RxNorm normalized name: PT886
DrugBank: PT886 (DB18471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.
Trial: NCT05482893
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: Cohort 1